Remegen

RemeGen Co., Ltd. (RemeGen) is a leading commercial-stage biopharmaceutical company based in China committed to providing solutions for patients with life-threatening illnesses. RemeGen's primary focus lies in discovering, developing, and commercializing innovative and differentiated biologic drugs, notably monoclonal antibodies and antibody-drug conjugates (ADCs), across key therapeutic areas such as autoimmune diseases, oncology, and ophthalmic disorders.

RemeGen's flagship product, Telitacicept (RC18), is the world's first and first-in-class recombinant B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) dual-target novel fusion protein product for injection. Telitacicept targets two critical cell-signaling molecules, BLyS and APRIL, involved in B-lymphocyte development, effectively reducing B-cell-mediated autoimmune responses implicated in several autoimmune diseases. In November 2023, Telitacicept received marketing approval from China's National Medical Products Administration (NMPA) for treating systemic lupus erythematosus (SLE).

Another groundbreaking product in RemeGen's portfolio is Disitamab Vedotin, China's first original antibody-drug conjugate (ADC). Disitamab Vedotin gained marketing approval from NMPA in June 2021 for treating HER2-expressing locally advanced or metastatic gastric cancer and in December 2021 for urothelial cancer. In August 2021, RemeGen secured an exclusive global (excluding Asia Pacific) licensing agreement with Seagen for Disitamab Vedotin, with potential milestone payments up to USD 2.6 billion and sales royalties ranging from high single digits to over 15%.

RemeGen's product pipeline encompasses numerous innovative drugs in various stages of research, development, and commercialization, including RC28, a dual-target VEGF/FGF innovative fusion protein with potential as a first-in-class ophthalmic treatment, currently in Phase 3 clinical trials.